STAT Plus: The biotech scorecard for the third quarter: 12 stock-moving occasions to look at

Here is STAT’s Biotech Scorecard, our common ledger of stock-moving biotech occasions, for the third quarter.

Amarin’s (AMRN) inventory value may transfer most on an occasion not taking place — that’s, if the FDA decides to not schedule an advisory committee assembly to evaluation Vascepa, the corporate’s coronary heart drug derived from fish oil. Amarin is in search of approval for an enlargement of the Vascepa label to incorporate information from a big medical trial that confirmed a 25% discount within the danger of unhealthy cardiovascular occasions like coronary heart assault and strokes. 

Unlock this text by subscribing to STAT Plus and luxuriate in your first 30 days free!


What’s it?

STAT Plus is a premium subscription that delivers day by day market-moving biopharma protection and in-depth science reporting from a staff with a long time of business expertise.

What’s included?

Authoritative biopharma protection and evaluation, interviews with business pioneers, coverage evaluation, and first seems to be at innovative laboratories and early stage analysis
Subscriber-only networking occasions and panel discussions throughout the nation
Month-to-month subscriber-only stay chats with our reporters and consultants within the area
Discounted tickets to business occasions and early-bird entry to business studies